At a major upcoming conference, new presentations will showcase the broad application of Natera's Signatera in oncology, including results from trials in bladder, colorectal, lung, endometrial, ovarian, and breast cancers, emphasizing its role in treatment response, recurrence detection, and early screening.

These studies highlight the growing use of circulating tumor DNA (ctDNA) for monitoring treatment response and early detection across various cancer types, with specific sessions dedicated to non-small cell lung cancer, endometrial, ovarian, renal cell carcinoma, and colorectal cancer.

Natera operates ISO 13485-certified and CAP-accredited laboratories in Texas and California, supporting its mission to integrate personalized genetic testing into standard oncology care to improve early intervention and treatment outcomes.

Supported by over 300 peer-reviewed publications, Natera continues to advance its personalized genetic testing capabilities within the clinical setting.

A highlight will be the presentation of the IMvigor011 trial, sponsored by Genentech, which is the first prospective phase III study in muscle-invasive bladder cancer using a molecular residual disease (MRD)-guided approach, with positive topline results indicating Signatera’s ability to predict disease-free and overall survival.

The IMvigor011 trial, scheduled for a Presidential Symposium on October 20, demonstrates that Signatera can identify bladder cancer patients most likely to benefit from adjuvant Tecentriq (atezolizumab), potentially reshaping treatment strategies.

Matthew Galsky, M.D., emphasized that across multiple Phase 3 trials, Signatera MRD can help select bladder cancer patients for adjuvant immunotherapy, potentially transforming clinical practice.

Natera’s chief medical officer, Minetta Liu, highlighted the increasing impact of bespoke MRD assessment in personalizing cancer treatment and improving patient outcomes, supported by diverse datasets across multiple cancer types.

Liu also emphasized that these datasets demonstrate the expanding role of personalized MRD testing in cancer detection and monitoring.

Natera will present 14 studies at the European Society for Medical Oncology (ESMO) Congress in Berlin from October 17 to 21, showcasing its leadership in MRD testing across various cancers, including six oral presentations.

Among these, several studies will focus on Signatera’s expanding role, including definitive predictive data in adjuvant bladder cancer.

Data from the Phase 3 CheckMate 274 trial will be presented, showing that Signatera-positive patients treated with nivolumab had more than double the disease-free survival compared to placebo (7.4 vs 2.8 months), with no significant benefit observed in Signatera-negative patients.